Patient info Open main menu

Fluomizin 10 mg vaginal tablets – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine status: No longer supplied Details

Medicine strength:
10 mg
Contains active substance:

Patient leaflet - Fluomizin 10 mg vaginal tablets

1. WHAT FLUOMIZIN IS AND WHAT IT IS USED FOR

Dequalinium chloride, the active ingredient in Fluomizin, belongs to the family of anti-infective and antiseptic drugs. Dequalinium chloride is active against the bacteria which cause bacterial vaginosis.

Fluomizin is used for the treatment of bacterial vaginosis.

It is inserted into the vagina for treatment at the site of infection.

You must talk to a doctor if you do not feel better or if you feel worse after 6 days.

  1. 2. WHAT YOU NEED TO KNOW

BEFORE YOU USE FLUOMIZIN

Do not use Fluomizin:

  • if you are allergic to the active substance dequalinium chloride or any of the other in-

    gredients of this medicine (listed in section 6).

  • if you have ulcers on your vagina or cervix.
  • if you have not yet had your first period.

Warnings and precautions

Intravaginal use of soaps, spermicides and vaginal douches (vaginal washes) is not recommended during treatment with Fluomizin.

As with all vaginal infections, unprotected sexual intercourse during treatment with Fluomizin is not recommended.

Fluomizin does not reduce the effectiveness of latex condoms.

This product may reduce the effectiveness of non-latex condoms or diaphragms. Consequently, you should use alternative methods of contracep- tion for at least 12 hours following the treatment.

Do not use Fluomizin within 12 hours before birth to minimize exposure of the newborn to dequalinium chloride. Please inform your doctor otherwise.

You should stop the treatment during the heavy bleeding period of your menstruation and resume afterwards.

You should talk to your doctor if the symptoms persist at the end of the treatment or in case the symptoms return.

Children and adolescents

There is insufficient experience of the use of Fluomizin in children and adolescents under 18 years of age.

Women above 55 years and elderly

There is insufficient experience of the use of Fluomizin in women above 55 years.

Other medicines and Fluomizin

Please tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.

Pregnancy and breast-feeding

If you are pregnant, think you may be pregnant or plan to have a baby ask your doctor or pharmacist for advice before using Fluomizin.

Tell your doctor or pharmacist if you are breast-feeding or if you plan to breast-feed.

Based on previous experience and since Fluomizin acts locally, no harmful effects on pregnancy and/or the unborn and breast fed infant are expected. Fluomizin should only be used during pregnancy and during breast- feeding if medically needed.

Ask your doctor or pharmacist for advice before taking any medicine.

Driving and using machines

Fluomizin is not likely to affect your ability to drive or operate any machinery. No studies have been performed.

3. HOW TO USE FLUOMIZIN

Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

The recommended dose is 1 vaginal tablet daily for 6 days.

Instructions for use

  • The medicine should be used for 6 days every evening before going to bed.
  • Wash your hands before opening the blister pack.
  • Lie down in a reclining position with the legs slightly bent. Insert one vaginal tablet deeply into the vagina.
  • You should stop the treatment during the heavy bleeding period of your menstruation and resume afterwards.
  • Do not stop treatment early, even if you no longer have any discomfort (e.g. itching, discharge, smell). A treatment of less than 6 days may result in your symptoms returning.
  • Fluomizin contains ingredients which do not dissolve completely, and the remains of the tablet are occasionally found in the under-wear. This won’t affect the effectiveness of the treatment. The tablet will not stain your underwear but for your own comfort you can use a sanitary towel or panty liner.
  • If your vagina is dry, the vaginal tablet might not dissolve and be discharged as intact tablet. As consequence, the treatment is not optimal. In this case the vaginal tablet can be moistened with a drop of water before insertion.

If you have the impression that the effect of Fluomizin is too strong or too weak, talk to your doctor or pharmacist.

Fluomizin 10 mg vaginal tablets dequalinium chloride PACKAGE LEAFLET: INFORMATION FOR THE USER

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor or your pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

    K-34077-1.2 If you use more Fluomizin than you should

Using a higher daily dose or increasing the recommended duration might increase the risk of vaginal ulcerations.

If you have accidentally used too many vaginal tablets, tell your doctor.

If you forget to use Fluomizin

Do not use a double dose to make up for a forgotten tablet.

If you stop using Fluomizin

A treatment of less than 6 days may result in a relapse. Therefore, do not stop treatment early, even when you have no discomfort (e.g. itching, discharge, smell) anymore.

If you have any further questions on the use of this medicine, ask your doctor or your pharmacist.

4. POSSIBLE SIDE EFFECTS

Like all medicines, this medicine can cause side effects, although not everybody gets them. Most of the side effects are mild and short lived.

Sometimes the symptoms of vaginal infections (such as itching, burning and discharge) can get worse at the beginning of the treatment, before they start to get better. You should continue with the treatment, but if the complaints persist see your doctor for advice as soon as possible.

Common (may affect up to 1 in 10 people)

  • Vaginal discharge; vaginal itching or vaginal burning;
  • Vaginal yeast infection (thrush).

Uncommon (may affect up to 1 in 100 people)

  • Vaginal bleeding; vaginal pain;
  • Inflammation of the vagina (vaginitis) and vulva;
  • Bacterial vaginosis;
  • Fungal skin infections;
  • Headache;
  • Nausea.

Not known (frequency cannot be estimated from the available data)

  • Ulcerations of vaginal mucosa, if the lining of the vagina was already damaged before treatment;
  • Uterine bleeding;
  • Vaginal redness, vaginal dryness;
  • Inflammation of the bladder (cystitis);
  • Allergic reaction with symptoms like rash, swelling or itching;
  • Fever.

Reporting of side effects

If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.

5. HOW TO STORE FLUOMIZIN

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and the blister. The expiry date refers to the last day of that month.

This medicine does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. CONTENTS OF THE PACK AND OTHER INFORMATION

What Fluomizin contains

  • The active substance is dequalinium chloride.

    • Each vaginal tablet contains 10 mg dequalinium chloride.
    • The other ingredients are lactose monohydrate, cellulose, microcrystalline and magnesium stearate.

What Fluomizin looks like and contents of the pack

Fluomizin vaginal tablets are white or almost white, oval and biconvex with approximate dimension of length: 19 mm, width: 12 mm, and thickness: 6.3 mm.

The vaginal tablets are available in packs containing a blister of 6 tablets.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder:

Gedeon Richter Plc.

Gyömrői út 19-21.

Budapest H-1103

Hungary

Manufacturer:

Haupt Pharma Amareg GmbH

Donaustaufer Strasse 378

93055 Regensburg

Germany

This medicinal product is authorised in the Member States of the EEA under the follo-wing names:

Member State: Medicinal Product Name: Germany - Fluomizin 10 mg

Vaginaltabletten

The Czech Republic - Naxyl 10 mg vaginálni tablety

Belgium - Fluomizin 10 mg tablet-ten voor vaginaal gebruik

  • Fluomizin 10 mg compri-més vaginaux
  • Fluomizin 10 mg

    Vaginaltabletten

Italy - Fluomizin 10 mg com-presse vaginali

Luxemburg - Fluomizin 10 mg compri-més vaginaux

Austria - Fluomizin 10 mg

Vaginaltabletten

Poland - Fluomizin 10 mg tabletki dopochwowe

Portugal - Fluomizin 10 mg compri-midos vaginais

Slovakia - Fluomizin 10 mg vaginál-ne tablety

Spain - Fluomizin 10 mg compri-midos vaginales

Finland - Donaxyl 10 mg emötin-puikko, tabletti

Hungary - Fluomizin 10 mg hüvely-tabletta

Norway - Donaxyl 10 mg vaginal-tabletter

Sweden - Donaxyl 10 mg vaginal-tabletter

The United Kingdom - Fluomizin 10 mg vaginal tablets

Estonia - Donaxyl 10 mg vaginaal-ne tablett

France - Vablys 10 mg comprimés vaginaux

Croatia - Fluomizin 10 mg tablete za rodnicu

Lithuania - Donaxyl 10 mg makšties tabletės

Latvia - Donaxyl 10 mg vaginālās tabletes

Slovenia - Fluomizin 10 mg vaginal-ne tablete

This leaflet was last revised in March 2026 Project: PIL-FluTb380-ROT-UK-3800017-321524-2025-03 Document description:

Version: 6

Version ID: 00002_0000289660

Downloaded: Mar 20, 2026 at 3:59 PM GMT+01:00 By: Maraia, Ivana (MARAIAI)

Approval state: Draft

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 04854/0194

Last revision stated in the text: March 2026 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Fluomizin 10 mg vaginal tablets

Active substance Dequalinium
Strength 10 mg
Pharmaceutical form Vaginal tablet
The vaginal tablets are white or almost white, oval and biconvex with approximate dimension of length: 19mm, width: 12mm, and thickness: 6.3mm.
How is it taken Vaginal
Excipients Lactose monohydrate, Cellulose, microcrystalline, Magnesium stearate
Is it available? No, all its packs are listed as discontinued (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life 3 years
Storage This medicinal product does not require any special storage conditions.
Drug group (ATC) Gynaecological anti-infective and antiseptic, Quinoline derivatives
  1. G Genito urinary system and sex hormones
    1. G01 Gynecological antiinfectives and antiseptics
      1. G01A Antiinfectives and antiseptics, excl. combinations with corticosteroids
        1. G01AC Quinoline gynecological antiinfectives
          1. G01AC05 dequalinium
Marketing authorisation PL 04854/0194 (first authorised 30 June 2015)
Marketing authorisation holder Gedeon Richter Plc.
Codes BNF 07020200

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.2.0 of 19 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.